Comparison of plasma and CSF Neurofilament-light in an MS trial

1 Department of Pharmacology and Clinical Neuroscience, Umeå University, Umeå, Sweden 2 Department of Psychiatry and Neurochemistry; Institute of Neuroscience and Physiology at Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden 3 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden 4 Department of Molecular Neuroscience, UCL Institute of Neurology, Queen Square, London, UK 5 UK Dementia Research Institute at UCL, London, UK 6 Department of Neurology, Faculty of Medicine and Health, Örebro University, Örebro,

[1]  K. Blennow,et al.  Plasma neurofilament light chain levels in patients with MS switching from injectable therapies to fingolimod , 2018, Multiple sclerosis.

[2]  P. Calabresi,et al.  A new enzyme-linked immunosorbent assay for neurofilament light in cerebrospinal fluid: analytical validation and clinical evaluation , 2018, Alzheimer's Research & Therapy.

[3]  C. Vedeler,et al.  Neurofilament light chain predicts disease activity in relapsing-remitting MS , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[4]  R. Marrie.  Serum neurofilament light chain in relapsing-remitting MS , 2017, Neurology: Neuroimmunology & Neuroinflammation.

[5]  K. Blennow,et al.  Monitoring disease activity in multiple sclerosis using serum neurofilament light protein , 2017, Neurology.

[6]  Ludwig Kappos,et al.  Serum Neurofilament light: A biomarker of neuronal damage in multiple sclerosis , 2017, Annals of neurology.

[7]  K. Blennow,et al.  Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing‐remitting multiple sclerosis , 2017, Journal of neurochemistry.

[8]  Henrik Zetterberg,et al.  Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa , 2016, Clinical chemistry and laboratory medicine.

[9]  M. Jorge Cardoso,et al.  Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia , 2016, Neurology.

[10]  K. Blennow,et al.  Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[11]  R. Birgander,et al.  Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab , 2016, Neurology.

[12]  M. Staufenbiel,et al.  Neurofilament Light Chain in Blood and CSF as Marker of Disease Progression in Mouse Models and in Neurodegenerative Diseases , 2016, Neuron.

[13]  Cristina Granziera,et al.  Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity , 2016, Multiple sclerosis.

[14]  Henrik Zetterberg,et al.  Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction , 2015, PloS one.

[15]  Ludwig Kappos,et al.  Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome , 2015, Journal of Neurology, Neurosurgery & Psychiatry.

[16]  H. Zetterberg,et al.  Assessing tissue damage in multiple sclerosis: a biomarker approach , 2014, Acta neurologica Scandinavica.

[17]  Michael Khalil,et al.  Neurofilaments as biomarkers in multiple sclerosis , 2012, Multiple sclerosis.

[18]  Frederik Barkhof,et al.  The changing face of multiple sclerosis clinical trial populations , 2011, Current medical research and opinion.

[19]  N. Norgren,et al.  Neurofilament and glial fibrillary acidic protein in multiple sclerosis , 2004, Neurology.

[20]  L. Rosengren,et al.  Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis , 1998, Journal of neurology, neurosurgery, and psychiatry.

[21]  Paul C. Letourneau.  Intrinsic determinants of neuronal form and function edited by R. J. Lasek and M. M. Black, Alan R. Liss, 1988. US$120.00 (xvii + 591 pages) ISBN 0 8451 2739 X , 1989, Trends in Neurosciences.

[22]  A. Minagar.  Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab , 2011 .